You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBupivacaine
Accession NumberDB00297  (APRD00247)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA widely used local anesthetic agent. [PubChem]
Structure
Thumb
Synonyms
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Bupivacaina
Bupivacainum
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
racemic bupivacaine
External Identifiers
  • DUR-843
  • LAC-43
  • SKY-0402
  • SKY0402
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralHospira, Inc.1978-04-172016-11-01Us
Bupivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; RetrobulbarHospira, Inc.1978-04-172016-10-13Us
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; IntracaudalHospira, Inc.1978-04-172016-10-13Us
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; IntracaudalHospira, Inc.1978-04-172016-10-13Us
Bupivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; RetrobulbarHospira, Inc.1978-04-172016-10-13Us
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralHospira, Inc.1978-04-172016-10-20Us
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; IntracaudalHospira, Inc.1978-04-172016-10-13Us
Bupivacaine Hydrochloride Injection USPSolution5 mgEpidural; InfiltrationMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPSolution7.5 mgEpidural; RetrobulbarMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPSolution5 mgInfiltrationMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPSolution2.5 mgEpidural; InfiltrationMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USPSolution2.5 mgInfiltrationMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Bupivacaine Hydrochloride Injection USP .25%Solution2.5 mgEpidural; Infiltration; IntracaudalHospira Healthcare Corporation1996-07-302011-08-05Canada
Bupivacaine Hydrochloride Injection USP .50%Solution5 mgEpidural; Infiltration; IntracaudalHospira Healthcare Corporation1996-07-302011-08-05Canada
Bupivacaine Hydrochloride Injection USP .75%Solution7.5 mgEpidural; Infiltration; IntracaudalHospira Healthcare Corporation1996-07-302011-08-05Canada
Bupivacaine Injection BPSolution2.5 mgEpidural; InfiltrationSterimax Inc2016-05-20Not applicableCanada
Bupivacaine Injection BPSolution2.5 mgEpidural; InfiltrationAuro Pharma IncNot applicableNot applicableCanada
Bupivacaine Injection BPSolution5 mgEpidural; InfiltrationAuro Pharma IncNot applicableNot applicableCanada
Bupivacaine Injection BPSolution5 mgEpidural; InfiltrationSterimax Inc2016-05-20Not applicableCanada
ExparelInjection, suspension, liposomal13.3 mg/mLInfiltrationPacira Pharmaceuticals Inc.2016-01-01Not applicableUs
ExparelInjection, suspension, liposomal13.3 mg/mLInfiltrationPacira Pharmaceuticals Inc.2012-01-01Not applicableUs
Jamp-bupivacaineSolution2.5 mgEpidural; InfiltrationJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-bupivacaineSolution2.5 mgInfiltrationJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-bupivacaineSolution5 mgEpidural; InfiltrationJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-bupivacaineSolution5 mgInfiltrationJamp Pharma CorporationNot applicableNot applicableCanada
MarcaineInjection, solution5 mg/mLEpiduralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
MarcaineInjection, solution5 mg/mLEpiduralREMEDYREPACK INC.2013-06-122017-11-04Us
MarcaineInjection, solution5 mg/mLEpiduralREMEDYREPACK INC.2015-03-07Not applicableUs
MarcaineInjection, solution7.5 mg/mLEpidural; RetrobulbarHospira, Inc.1972-10-03Not applicableUs
MarcaineInjection, solution7.5 mg/mLEpidural; RetrobulbarA S Medication Solutions Llc2009-09-09Not applicableUs
MarcaineInjection, solution2.5 mg/mLInfiltration; PerineuralHospira, Inc.1972-10-03Not applicableUs
MarcaineInjection, solution5 mg/mLPerineuralA S Medication Solutions2005-11-30Not applicableUs
MarcaineInjection, solution2.5 mg/mLInfiltrationPhysicians Total Care, Inc.2009-09-08Not applicableUs
MarcaineInjection, solution2.5 mg/mLEpidural; Infiltration; Intracaudal; PerineuralHospira, Inc.1972-10-03Not applicableUs
MarcaineInjection, solution5 mg/mLPerineuralHospira, Inc.1972-10-03Not applicableUs
MarcaineInjection, solution2.5 mg/mLEpidural; InfiltrationGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
MarcaineInjection, solution2.5 mg/mLEpidural; InfiltrationCardinal Health2009-09-08Not applicableUs
MarcaineInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralHospira, Inc.1972-10-03Not applicableUs
Marcaine 0.25%Solution2.5 mgInfiltrationHospira Healthcare Corporation2008-10-08Not applicableCanada
Marcaine 0.25% Liq Prt 2.5mg/mlLiquid2.5 mgEpidural; InfiltrationSanofi Canada, Inc.1973-12-312001-08-10Canada
Marcaine 0.50%Solution5.0 mgInfiltrationHospira Healthcare Corporation2008-09-17Not applicableCanada
Marcaine 0.50% Liq Bin 5mg/mlLiquid5 mgEpidural; InfiltrationSanofi Canada, Inc.1973-12-312001-08-10Canada
Marcaine 0.75% Liq Prt 7.5mg/mlLiquid7.5 mgEpidural; RetrobulbarSanofi Canada, Inc.1974-12-312001-08-10Canada
Marcaine 0.75% Liq Spinal 7.5mg/mlLiquid7.5 mgIntraspinalSanofi Canada, Inc.1979-12-312001-08-10Canada
Marcaine 2.5 mg/mlSolution2.5 mgEpidural; InfiltrationHospira Healthcare Corporation2000-12-01Not applicableCanada
Marcaine 5 mg/mlSolution5.0 mgEpidural; InfiltrationHospira Healthcare Corporation2000-12-01Not applicableCanada
Marcaine 7.5 mg/mlSolution7.5 mgEpidural; RetrobulbarHospira Healthcare Corporation2001-09-15Not applicableCanada
Marcaine SpinalInjection, solution7.5 mg/mLSubarachnoidHospira, Inc.1984-05-04Not applicableUs
Marcaine Spinal 7.5 mg/mlSolution7.5 mgIntraspinalHospira Healthcare Corporation2000-12-01Not applicableCanada
Marvona SuikInjection, solution5 mg/mLEpidural; InfiltrationAsclemed Usa, Inc.2009-09-08Not applicableUs
Readysharp BupivacaineInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralTerrain Pharmaceuticals2005-08-16Not applicableUs
SensorcaineInjection, solution2.5 mg/mLInfiltration; PerineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
SensorcaineInjection, solution5 mg/mLPerineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaine 0.25%Liquid2.5 mgEpidural; InfiltrationAstrazeneca Canada Inc1994-12-31Not applicableCanada
Sensorcaine 0.5%Liquid5 mgEpidural; InfiltrationAstrazeneca Canada Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BupivacaineInjection, solution7.5 mg/mLSubarachnoidHospira, Inc.1987-12-11Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLPerineuralHospira, Inc.1987-03-03Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; IntracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; IntracaudalCardinal Health2010-01-06Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; IntracaudalREMEDYREPACK INC.2016-06-15Not applicableUs
Bupivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; RetrobulbarAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine HydrochlorideInjection, solution7.5 mg/mLIntraspinalClaris Lifesciences Inc.2016-08-08Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLInfiltration; PerineuralHospira, Inc.1987-02-17Not applicableUs
Bupivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; RetrobulbarHospira, Inc.1987-03-03Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; IntracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; Intracaudal; PerineuralHospira, Inc.1987-02-17Not applicableUs
Bupivacaine HydrochlorideInjection2.5 mg/mLInfiltrationGeneral Injectables & Vaccines, Inc2010-07-01Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; IntracaudalCardinal Health2010-01-07Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLInfiltration; PerineuralAuro Medics Pharma Llc2016-05-13Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralHospira, Inc.1987-03-03Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; IntracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine HydrochlorideInjection5 mg/mLInfiltrationGeneral Injectables & Vaccines, Inc2010-07-01Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Infiltration; IntracaudalCardinal Health2010-01-07Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLPerineuralAuro Medics Pharma Llc2016-05-13Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; IntracaudalAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralHospira, Inc.1987-02-17Not applicableUs
Bupivacaine HydrochlorideInjection, solution7.5 mg/mLEpidural; RetrobulbarAuro Medics Pharma Llc2013-11-05Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; Intracaudal; PerineuralHospira, Inc.1987-03-032016-11-01Us
Bupivacaine HydrochlorideInjection, solution5 mg/mLEpidural; IntracaudalREMEDYREPACK INC.2016-06-07Not applicableUs
Bupivacaine HydrochlorideInjection, solution2.5 mg/mLEpidural; Infiltration; IntracaudalCardinal Health2010-01-06Not applicableUs
SensorcaineInjection, solution5 mg/mLPerineuralGeneral Injectables & Vaccines, Inc2011-10-18Not applicableUs
SensorcaineInjection, solution2.5 mg/mLInfiltration; PerineuralGeneral Injectables & Vaccines, Inc2011-10-17Not applicableUs
Sensorcaine MpfInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralGeneral Injectables & Vaccines, Inc2011-10-26Not applicableUs
Sensorcaine MpfInjection, solution7.5 mg/mLEpidural; RetrobulbarFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaine MpfInjection, solution2.5 mg/mLEpidural; Infiltration; Intracaudal; PerineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Sensorcaine MpfInjection, solution7.5 mg/mLSubarachnoidFresenius Kabi USA, LLC2010-05-25Not applicableUs
Sensorcaine MpfInjection, solution5 mg/mLEpidural; Intracaudal; PerineuralFresenius Kabi USA, LLC2010-11-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BupivanSun
CarbostesinAstraZeneca
MarcainAstraZeneca
MarcainaAstraZeneca
Sensorcaine-MPFAstra Zeneca
Brand mixtures
NameLabellerIngredients
Bupivacaine HCl 0.5% and Epinephrine 1:200,000 InjectionNovocol Pharmaceutical Of Canada Inc
Bupivacaine Hydrochloride and EpinephrineGeneral Injectables & Vaccines, Inc
Disposable Convenience Kit (single Shot Epidural)True Fit Rx Llc
Fentanyl Citrate, Bupivacaine HClCantrell Drug Company
Gapeam BudibacAlvix Laboratories, LLC
MarcaineCarestream Health Inc.
Marcaine 0.5% and Epinephrine 1:200,000 LiqKodak Canada Inc.
Marcaine E 0.25% Liq PrtSanofi Canada, Inc.
Marcaine E 2.5 mg/mlHospira Healthcare Corporation
Marcaine E 5.0 mg/mlHospira Healthcare Corporation
Marcaine E Liq Prt 0.50%Sanofi Canada, Inc.
Marcaine With EpinephrinePhysicians Total Care, Inc.
Physicians Ez Use M-predProficient Rx LP
Readysharp-ATerrain Pharmaceuticals
Readysharp-KTerrain Pharmaceuticals
Readysharp-p40Terrain Pharmaceuticals
Readysharp-p80Terrain Pharmaceuticals
SensorcaineFresenius Kabi USA, LLC
Sensorcaine 0.25% With EpinephrineAstrazeneca Canada Inc
Sensorcaine 0.5% With EpinephrineAstrazeneca Canada Inc
Sensorcaine ForteDentsply Canada Limited
Sensorcaine MpfCardinal Health
VivacaineSeptodont, Inc.
Vivacaine (bupivacaine HCl 0.5% & Epinephrine 1:200,000 Inj, USP)Septodont Inc
Salts
Name/CASStructureProperties
Bupivacaine hydrochloride
18010-40-7
Thumb
  • InChI Key: SIEYLFHKZGLBNX-UHFFFAOYSA-N
  • Monoisotopic Mass: 324.196841267
  • Average Mass: 324.889
DBSALT000202
Bupivacaine hydrochloride monohydrate
73360-54-0
Thumb
  • InChI Key: HUCIWBPMHXGLFM-UHFFFAOYSA-N
  • Monoisotopic Mass: 342.2074059
  • Average Mass: 342.91
DBSALT001512
Categories
UNIIY8335394RO
CAS number38396-39-3
WeightAverage: 288.4277
Monoisotopic: 288.220163528
Chemical FormulaC18H28N2O
InChI KeyLEBVLXFERQHONN-UHFFFAOYSA-N
InChI
InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
IUPAC Name
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
SMILES
CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Pharmacology
IndicationFor the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
Structured Indications Not Available
PharmacodynamicsBupivacaine is a widely used local anesthetic agent. Bupivacaine is often administered by spinal injection prior to total hip arthroplasty. It is also commonly injected into surgical wound sites to reduce pain for up to 20 hours after surgery. In comparison to other local anesthetics it has a long duration of action. It is also the most toxic to the heart when administered in large doses. This problem has led to the use of other long-acting local anaesthetics:ropivacaine and levobupivacaine. Levobupivacaine is a derivative, specifically an enantiomer, of bupivacaine. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias and to cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression or both.
Mechanism of actionLocal anesthetics such as bupivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Bupivacaine binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, which prevents depolarization. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone. The analgesic effects of Bupivicaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 10 subunit alphaProteinyes
inhibitor
HumanQ9Y5Y9 details
Prostaglandin E2 receptor EP1 subtypeProteinunknown
other/unknown
HumanP34995 details
Related Articles
AbsorptionThe rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
Volume of distributionNot Available
Protein binding95%
Metabolism

Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4.

SubstrateEnzymesProduct
Bupivacaine
Not Available
2,6-pipecoloxylidineDetails
Route of eliminationOnly 6% of bupivacaine is excreted unchanged in the urine.
Half life2.7 hours in adults and 8.1 hours in neonates
ClearanceNot Available
ToxicityThe mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. The intravenous and subcutaneous LD 50 in mice is 6 to 8 mg/kg and 38 to 54 mg/kg respectively. Recent clinical data from patients experiencing local anesthetic induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis with bupivacaine within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bupivacaine Action PathwayDrug actionSMP00393
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Bupivacaine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bupivacaine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Bupivacaine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololThe serum concentration of Bupivacaine can be increased when it is combined with Alprenolol.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Bupivacaine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bupivacaine.Approved
AmiodaroneThe metabolism of Bupivacaine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bupivacaine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bupivacaine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Bupivacaine.Approved
Aop200704The serum concentration of Bupivacaine can be increased when it is combined with Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bupivacaine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Bupivacaine.Approved
AprepitantThe serum concentration of Bupivacaine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bupivacaine.Approved, Investigational
ArmodafinilThe metabolism of Bupivacaine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Bupivacaine can be increased when it is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bupivacaine.Approved, Investigational
ArtemetherThe metabolism of Bupivacaine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Asenapine.Approved
AtazanavirThe metabolism of Bupivacaine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Bupivacaine can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Bupivacaine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Azaperone.Vet Approved
AzelastineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bupivacaine.Approved
AzithromycinThe metabolism of Bupivacaine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Bupivacaine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bupivacaine.Approved
BefunololThe serum concentration of Bupivacaine can be increased when it is combined with Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bupivacaine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bupivacaine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Bupivacaine.Approved, Withdrawn
BetaxololThe serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.Approved
BevantololThe serum concentration of Bupivacaine can be increased when it is combined with Bevantolol.Approved
BexaroteneThe serum concentration of Bupivacaine can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Bupivacaine can be decreased when combined with Boceprevir.Approved
BopindololThe serum concentration of Bupivacaine can be increased when it is combined with Bopindolol.Approved
BortezomibThe metabolism of Bupivacaine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bupivacaine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Bupivacaine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupivacaine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bupivacaine can be increased when it is combined with Bucindolol.Investigational
BufuralolThe serum concentration of Bupivacaine can be increased when it is combined with Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bupivacaine.Approved
BupranololThe serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.Approved
BuprenorphineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupivacaine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bupivacaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butorphanol.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Bupivacaine can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bupivacaine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bupivacaine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Bupivacaine.Approved
CarbamazepineThe metabolism of Bupivacaine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carisoprodol.Approved
CarteololThe serum concentration of Bupivacaine can be increased when it is combined with Carteolol.Approved
CarvedilolThe serum concentration of Bupivacaine can be increased when it is combined with Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Bupivacaine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Bupivacaine can be increased when it is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Bupivacaine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Bupivacaine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Bupivacaine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bupivacaine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Bupivacaine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bupivacaine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Bupivacaine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bupivacaine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cilnidipine.Approved
CimetidineThe metabolism of Bupivacaine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Bupivacaine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Bupivacaine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Bupivacaine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bupivacaine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Bupivacaine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clidinium.Approved
ClobazamThe metabolism of Bupivacaine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Bupivacaine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Bupivacaine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Bupivacaine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Bupivacaine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bupivacaine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Bupivacaine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Bupivacaine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Bupivacaine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Bupivacaine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Bupivacaine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Bupivacaine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bupivacaine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Bupivacaine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Bupivacaine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bupivacaine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desflurane.Approved
DesipramineThe metabolism of Bupivacaine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Bupivacaine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bupivacaine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Bupivacaine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Bupivacaine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Bupivacaine.Approved
DiphenhydramineThe metabolism of Bupivacaine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Bupivacaine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bupivacaine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Bupivacaine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Bupivacaine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Illicit
DronedaroneThe metabolism of Bupivacaine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Drotebanol.Experimental, Illicit
DuloxetineBupivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Bupivacaine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Bupivacaine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Efonidipine.Approved
EliglustatThe metabolism of Bupivacaine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bupivacaine.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bupivacaine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Bupivacaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bupivacaine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bupivacaine.Approved
ErythromycinThe metabolism of Bupivacaine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Bupivacaine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe serum concentration of Bupivacaine can be increased when it is combined with Esmolol.Approved
EsomeprazoleThe metabolism of Bupivacaine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bupivacaine.Approved
EthanolBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Bupivacaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Bupivacaine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Bupivacaine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Bupivacaine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Bupivacaine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Bupivacaine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Bupivacaine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bupivacaine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bupivacaine.Approved
FosphenytoinThe metabolism of Bupivacaine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bupivacaine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bupivacaine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Bupivacaine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Bupivacaine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bupivacaine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Bupivacaine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bupivacaine.Approved, Vet Approved
HydrocodoneBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved
IdelalisibThe serum concentration of Bupivacaine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Bupivacaine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Imidapril.Investigational
ImipramineThe metabolism of Bupivacaine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bupivacaine.Approved
IndenololThe serum concentration of Bupivacaine can be increased when it is combined with Indenolol.Withdrawn
IndinavirThe metabolism of Bupivacaine can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bupivacaine.Approved, Investigational
IsavuconazoniumThe metabolism of Bupivacaine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Bupivacaine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bupivacaine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bupivacaine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bupivacaine.Approved, Withdrawn
IsradipineThe metabolism of Bupivacaine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bupivacaine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bupivacaine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Bupivacaine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe serum concentration of Bupivacaine can be increased when it is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levetiracetam.Approved, Investigational
LevobunololThe serum concentration of Bupivacaine can be increased when it is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levocetirizine.Approved
LevodopaBupivacaine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levosimendan.Approved, Investigational
LidocaineThe metabolism of Bupivacaine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bupivacaine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Bupivacaine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Bupivacaine.Approved
LorcaserinThe metabolism of Bupivacaine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bupivacaine.Approved
LovastatinThe metabolism of Bupivacaine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Bupivacaine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bupivacaine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Bupivacaine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Bupivacaine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bupivacaine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Metaxalone.Approved
MethadoneThe metabolism of Bupivacaine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bupivacaine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methohexital.Approved
MethotrimeprazineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bupivacaine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Bupivacaine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methylphenobarbital.Approved
MetipranololThe serum concentration of Bupivacaine can be increased when it is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bupivacaine.Approved
MetoprololThe serum concentration of Bupivacaine can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineBupivacaine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Bupivacaine can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Bupivacaine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bupivacaine.Approved
MirabegronThe metabolism of Bupivacaine can be decreased when combined with Mirabegron.Approved
MirtazapineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Bupivacaine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Bupivacaine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Bupivacaine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Bupivacaine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bupivacaine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
NadololThe serum concentration of Bupivacaine can be increased when it is combined with Nadolol.Approved
NafcillinThe serum concentration of Bupivacaine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Bupivacaine.Approved, Investigational
NefazodoneThe metabolism of Bupivacaine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bupivacaine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Bupivacaine.Approved, Investigational
NetupitantThe serum concentration of Bupivacaine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bupivacaine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Bupivacaine can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bupivacaine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Bupivacaine.Approved
NilotinibThe metabolism of Bupivacaine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bupivacaine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bupivacaine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bupivacaine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bupivacaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Bupivacaine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bupivacaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Bupivacaine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Opium.Approved, Illicit
OrphenadrineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Bupivacaine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxetacaine.Investigational
OxprenololThe serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bupivacaine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Bupivacaine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Bupivacaine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Bupivacaine.Approved
ParaldehydeBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Bupivacaine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Bupivacaine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Bupivacaine can be increased when it is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Bupivacaine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Bupivacaine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Bupivacaine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phentolamine.Approved
PhenytoinThe metabolism of Bupivacaine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pimozide.Approved
PindololThe serum concentration of Bupivacaine can be increased when it is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Bupivacaine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Bupivacaine can be increased when it is combined with Practolol.Approved
PramipexoleBupivacaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Bupivacaine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Bupivacaine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Bupivacaine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe metabolism of Bupivacaine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Bupivacaine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Bupivacaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Bupivacaine.Approved, Investigational
QuinidineThe metabolism of Bupivacaine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Bupivacaine can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bupivacaine.Approved
RanolazineThe metabolism of Bupivacaine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bupivacaine.Approved
RifabutinThe metabolism of Bupivacaine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bupivacaine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bupivacaine can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Bupivacaine.Approved
RisperidoneBupivacaine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Bupivacaine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Bupivacaine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Romifidine.Vet Approved
RopiniroleBupivacaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bupivacaine.Approved
RotigotineBupivacaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Bupivacaine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Bupivacaine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Bupivacaine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Bupivacaine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Bupivacaine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Bupivacaine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bupivacaine can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved
SotalolThe serum concentration of Bupivacaine can be increased when it is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bupivacaine.Approved
St. John's WortThe serum concentration of Bupivacaine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Bupivacaine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Bupivacaine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.Approved
SuvorexantBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptBupivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TelaprevirThe metabolism of Bupivacaine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Bupivacaine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bupivacaine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bupivacaine.Approved
TenofovirThe metabolism of Bupivacaine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Bupivacaine.Approved
TerbinafineThe metabolism of Bupivacaine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Bupivacaine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrodotoxin.Investigational
ThalidomideBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Bupivacaine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Bupivacaine can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Bupivacaine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Bupivacaine can be increased when it is combined with Timolol.Approved
TipranavirThe metabolism of Bupivacaine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Bupivacaine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bupivacaine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bupivacaine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bupivacaine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bupivacaine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Bupivacaine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bupivacaine.Approved, Investigational
VemurafenibThe serum concentration of Bupivacaine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Bupivacaine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Bupivacaine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Bupivacaine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Bupivacaine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zolazepam.Vet Approved
ZolpidemBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Thuresson, B. and Egner, B.P.H.; U.S. Patent 2,792,399; May 14, 1957; assigned to AB Bofors, Sweden.
Thuresson, B. and Pettersson, B.G.; US. Patent 2,955.1 11; October 4,1960; assigned to AB
Bofors, Sweden.

US2955111
General References
  1. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB: Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006 Jul;105(1):217-8. [PubMed:16810015 ]
  2. Picard J, Meek T: Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia. 2006 Feb;61(2):107-9. [PubMed:16430560 ]
  3. Link [Link]
External Links
ATC CodesN01BB51N01BB01
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (147 KB)
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9814
Blood Brain Barrier+0.936
Caco-2 permeable+0.6669
P-glycoprotein substrateSubstrate0.8435
P-glycoprotein inhibitor IInhibitor0.8582
P-glycoprotein inhibitor IINon-inhibitor0.7836
Renal organic cation transporterNon-inhibitor0.6471
CYP450 2C9 substrateNon-substrate0.7957
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.7045
CYP450 1A2 substrateInhibitor0.6863
CYP450 2C9 inhibitorNon-inhibitor0.9099
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.6205
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6066
Ames testNon AMES toxic0.8462
CarcinogenicityNon-carcinogens0.8859
BiodegradationNot ready biodegradable0.9729
Rat acute toxicity2.2574 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8283
hERG inhibition (predictor II)Inhibitor0.7851
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • International medicated systems ltd
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
InjectionInfiltration2.5 mg/mL
InjectionInfiltration5 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal2.5 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal5 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural2.5 mg/mL
Injection, solutionEpidural; Intracaudal5 mg/mL
Injection, solutionEpidural; Retrobulbar7.5 mg/mL
Injection, solutionIntraspinal7.5 mg/mL
InjectionEpidural; Infiltration; Intracaudal
Injection, solutionDental; Infiltration
Injection, solutionEpidural; Infiltration; Intracaudal
SolutionEpidural; Infiltration5 mg
SolutionInfiltration2.5 mg
SolutionInfiltration5 mg
SolutionEpidural; Infiltration; Intracaudal2.5 mg
SolutionEpidural; Infiltration; Intracaudal5 mg
SolutionEpidural; Infiltration; Intracaudal7.5 mg
Injection, suspension, liposomalInfiltration13.3 mg/mL
Injection, solutionEpidural
KitTopical
Injection, solutionEpidural5 mg/mL
Injection, solutionEpidural; Infiltration2.5 mg/mL
Injection, solutionInfiltration2.5 mg/mL
LiquidInfiltration
SolutionInfiltration5.0 mg
LiquidEpidural; Retrobulbar7.5 mg
LiquidIntraspinal7.5 mg
SolutionEpidural; Infiltration2.5 mg
SolutionEpidural; Infiltration5.0 mg
SolutionEpidural; Retrobulbar7.5 mg
LiquidEpidural; Infiltration
Injection, solutionSubarachnoid7.5 mg/mL
SolutionIntraspinal7.5 mg
Injection, solutionInfiltration
Injection, solutionEpidural; Infiltration5 mg/mL
Kit
KitEpidural; Infiltration; Intramuscular; Intrasynovial; Soft tissue; Topical
KitEpidural; Infiltration
KitEpidural; Infiltration; Intra-articular; Intramuscular; Topical
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
Injection, solutionInfiltration; Perineural
Injection, solutionInfiltration; Perineural2.5 mg/mL
Injection, solutionPerineural
Injection, solutionPerineural5 mg/mL
LiquidEpidural; Infiltration2.5 mg
SolutionEpidural; Infiltration
LiquidEpidural; Infiltration5 mg
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural
Injection, solutionEpidural; Intracaudal; Perineural
Injection, solutionEpidural; Intracaudal; Perineural5 mg/mL
Injection, solutionEpidural; Retrobulbar
Injection, solutionSubcutaneous
SolutionInfiltration
Prices
Unit descriptionCostUnit
Bupivacaine hcl powder18.36USD g
Sensorcaine-dextr 0.75% amp2.36USD ml
Marcaine spinal ampul0.93USD ml
Bupivacaine 0.5% on-q pump0.63USD ml
Bupivacaine hcl 0.5% on-q pump0.63USD ml
Bupivacaine 0.25% on-q pump0.62USD ml
Marcaine 0.25% vial0.26USD ml
Bupivacaine hcl-ns 0.0625%0.25USD ml
Bupivacaine-ns 0.1% on-q pump0.25USD ml
Sensorcaine 0.25% vial0.2USD ml
Bupivacaine hcl-ns 0.1%0.17USD ml
Bupivacaine hcl-ns 0.2%0.15USD ml
Bupivacaine 0.25% vial0.11USD ml
Bupivacaine 0.25% ampul0.1USD ml
Bupivacaine hcl-ns 0.125% bag0.1USD ml
Bupivacaine hcl-ns 0.25%0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8182835 No1998-09-182018-09-18Us
US8834921 No1998-09-182018-09-18Us
US9205052 No1998-09-182018-09-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point107-108 °CPhysProp
water solubility2400 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.41HANSCH,C ET AL. (1995)
pKa8.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0977 mg/mLALOGPS
logP3.31ALOGPS
logP4.52ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity90.19 m3·mol-1ChemAxon
Polarizability34.19 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.44 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-arylamide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med. 2010 Jan;20(1):16-21. doi: 10.1016/j.tcm.2010.03.002. [PubMed:20685573 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Prostaglandin e receptor activity
Specific Function:
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.
Gene Name:
PTGER1
Uniprot ID:
P34995
Molecular Weight:
41800.655 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Beloeil H, Gentili M, Benhamou D, Mazoit JX: The effect of a peripheral block on inflammation-induced prostaglandin E2 and cyclooxygenase expression in rats. Anesth Analg. 2009 Sep;109(3):943-50. doi: 10.1213/ane.0b013e3181aff25e. [PubMed:19690271 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gantenbein M, Attolini L, Bruguerolle B, Villard PH, Puyoou F, Durand A, Lacarelle B, Hardwigsen J, Le-Treut YP: Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5. [PubMed:10725304 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:43